BioSpace News Archive

The MemorialCare Heart & Vascular Institute at Long Beach Medical Center is now offering the WATCHMAN™ Left Atrial Appendage Closure Device for patients with atrial fibrillation (AFib).

StageZero Life Sciences, Ltd (TSX:SZLS) (“StageZero” or the “Company”) is pleased to report that shareholders voted in favour of all items of business, including the election of all nominee directors listed in the Company’s management information circular dated June 29, 2020 (the “Circular”), at its annual and special meeting of shareholders held on August 17, 2020 (the “Meeting”).

Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, ‘Aroa’ or the ‘Company’) has gained further validation for Endoform®, its flagship extracellular matrix (ECM), with a new study published in respected international peer-reviewed journal PLOS ONE.

Total revenue of $126.7 million, including net product sales of $89.7 million for Trokendi XR®, $23.7 million for Oxtellar XR®, and $10.6 million for the acquired Parkinson’s disease (PD) products Operating earnings of $45.5 million Completed acquisition of CNS portfolio of US WorldMeds on June 9, 2020 Executed a Development and Option Agreement with Navitor Pharmaceuticals, Inc. on SPN-820 (NV-5138) On track to launch SPN-812, if approved by the FDA, with shipments to the trade in December

Inhibrx, Inc. (“Inhibrx”) (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a price to the public of $17.00 per share.

Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, announced today the pricing of its upsized initial public offering of 5,348,837

This Approval Enables the Company to Sell its Product Lines to Hartsfield-Jackson Atlanta International Airport (ATL) via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnolog

Isotopia Molecular Imaging is pleased to announce that it has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for no-carrier-added Lutetium-177 (n.c.a. Lu177), a medical radioisotope.

A new clinical trial found consuming cranberry juice containing 44 mg of proanthocyanidins (or “PACs”) per 240-mL serving twice daily for eight weeks resulted in a 20% reduction in the H. pylori infection rate in Chinese adult participants, when compared to those consuming lower amounts of juice and a placebo

International Isotopes Inc. (OTCQB: INIS) (the “Company” or “INIS”) announces its financial results for the three and six months ended June 30, 2020.